{"id":"W4293652654","doi":"10.1016/j.jtct.2022.08.021","title":"Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Janssen Pharmaceuticals; Incyte; Fondazione IRCCS Policlinico San Matteo; Pharmacyclics; AbbVie; Jazz Pharmaceuticals; Novartis; Teva Pharmaceutical Industries; Gilead Sciences; GlaxoSmithKline; Amgen","keywords":"Ibrutinib; Medicine; Internal medicine; Clinical endpoint; Hematopoietic stem cell transplantation; Adverse effect; Refractory (planetary science); Graft-versus-host disease; Transplantation; Gastroenterology; Clinical trial; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002280661,0.0001658204,0.0002430519,0.00007088503,0.0002012136,0.00001498777,0.0001153324,0.0000207096,0.0003142735],"category_scores_gemma":[0.000004858095,0.0001131406,0.00009117066,0.0002442808,0.00007666948,0.00004247158,0.00001298599,0.0001111983,0.000005061254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001327677,"about_ca_system_score_gemma":0.001555259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006114367,"about_ca_topic_score_gemma":0.00002204251,"domain_scores_codex":[0.9983782,0.0002120996,0.0003270461,0.0003296162,0.0005509366,0.0002021157],"domain_scores_gemma":[0.9990317,0.0003321954,0.00009054095,0.0003842589,0.00003552277,0.0001258021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5398884,0.03499109,0.02405245,0.00079413,0.003839493,0.006271279,0.08973291,0.0004648053,0.1672973,0.0001965313,0.001417957,0.1310537],"study_design_scores_gemma":[0.8875496,0.02072204,0.04579928,0.0000358576,0.002234381,0.000054536,0.002829113,0.003969059,0.0208726,0.00003841218,0.01535715,0.0005379727],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835335,0.01352389,0.00006419441,0.000506271,0.0001221151,0.001325715,0.0007210117,0.00003510455,0.0001682143],"genre_scores_gemma":[0.9820392,0.01554651,0.00001756666,0.00007661624,0.0002492371,0.0001179559,0.001655791,0.00002351475,0.000273606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3476612,"threshold_uncertainty_score":0.461374,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04040375757232324,"score_gpt":0.3183749669695803,"score_spread":0.2779712093972571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}